Breaking News Instant updates and real-time market news.

MU

Micron

$56.50

2.51 (4.65%)

, GE

General Electric

$15.03

0.32 (2.18%)

07:35
05/17/18
05/17
07:35
05/17/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Wednesday in Micron (MU), General Electric (GE), Exxon Mobil (XOM), Wal-Mart (WMT), General Motors (GM), Cliffs Natural (CLF), Colgate Palmolive (CL), Weibo (WB), NRG Energy (NRG), and Immunomedics (IMMU).

MU

Micron

$56.50

2.51 (4.65%)

GE

General Electric

$15.03

0.32 (2.18%)

XOM

Exxon Mobil

$82.01

0.23 (0.28%)

WMT

Walmart

$86.07

1.56 (1.85%)

GM

General Motors

$38.03

1.07 (2.90%)

CLF

Cleveland-Cliffs

$8.74

0.165 (1.93%)

CL

Colgate-Palmolive

$62.09

0.45 (0.73%)

WB

Weibo

$103.85

-0.67 (-0.64%)

NRG

NRG Energy

$33.74

-0.01 (-0.03%)

IMMU

Immunomedics

$19.51

0.725 (3.86%)

  • 17

    May

  • 21

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 20

    Jun

MU Micron
$56.50

2.51 (4.65%)

05/15/18
STFL
05/15/18
NO CHANGE
Target $101
STFL
Buy
NAND flash negativity creates buying opportunity in Micron, says Stifel
Stifel analyst Kevin Cassidy said DRAM prices are tracking above his previous estimates for the May-ending quarter, while the NAND flash market "is growing and far from collapsing, as the bear case has it." The NAND flash negativity is overdone, creating buying opportunities in Micron (MU), Smart Global (SGH) and Western Digital (WDC), according to Cassidy. He raised his price target on Micron shares to $101 from $95 while maintaining a Buy rating on the stock. The firm also has Buy ratings on Smart Global and Western Digital.
05/16/18
MZHO
05/16/18
NO CHANGE
Target $70
MZHO
Buy
Micron analyst day could be a catalyst, says Mizuho
Micron's (MU) analyst day could be a catalyst for shares as it may reinforce a positive second half of 2018 outlook with iPhone/holiday build season, Mizuho analyst Vijay Rakesh tells investors in a research note. Further, the analyst believes NAND and DRAM pricing will remain stable exiting the June quarter. With Micron and Western Digital (WDC) off 10% from recent highs, Rakesh sees attractive entry points and remains a buyer. He has a Buy rating on Micron with a $70 price target.
05/16/18
RBCM
05/16/18
INITIATION
Target $80
RBCM
Outperform
Micron initiated with an Outperform at RBC Capital
RBC Capital analyst Amit Daryanani initiated Micron with an Outperform rating and a price target of $80, saying the company is offering exposure to DRAM and NAND memory market at an attractive valuation. While the down-price cycle in memory may not be over, the analyst contends that it is more "muted" than estimated, stating that Micron can still generate earnings and free cash flows in the current environment. Daryanani is also positive on Micron's position in the long term given the more diversified DRAM user base market with much more emphasis on mobile, reduced competition, and the potential for capital allocation.
05/16/18
05/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Buy at UBS. 2. uniQure (QURE) initiated with an Outperform at Wells Fargo. 3. Micron (MU) initiated with an Outperform at RBC Capital. 4. Spotify (SPOT) initiated with a Market Perform at Wells Fargo. 5. Tocagen (TOCA) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GE General Electric
$15.03

0.32 (2.18%)

05/04/18
JPMS
05/04/18
NO CHANGE
Target $11
JPMS
Underweight
GE really sold Industrial Solutions for $1.9B, not $2.6B, says JPMorgan
JPMorgan analyst Stephen Tusa says new disclosures in General Electric's quarterly filing show that the net proceeds from the Industrial Solutions sale will be $1.9B, not the headline $2.6B. This is partly because of taxes but also because of the company's disclose that "cash to be received by GE Capital for receivables originated in our Industrial Solutions business and sold to them," Tusa tells investors in a research note titled "GE Industrial Solutions: A Window Into Asset Sales and How $2.6 B Becomes $1.9 B, and Arguably Close to Zero." Further, he notes that the majority of pension liabilities are staying with GE. This is "another bite out of the proceeds," Tusa writes. He believes assets sales such as this are "unattractive for the shareholder, and should be viewed as such by ratings agencies, which remain seemingly and surprisingly patient and accommodating." The analyst keeps an Underweight rating on General Electric with an $11 price target.
05/10/18
JPMS
05/10/18
NO CHANGE
Target $11
JPMS
Underweight
Spread between GE's adjusted, GAAP results widest on record, says JPMorgan
The difference between General Electric's "adjusted" earnings per share, which is being used by consensus and retail investors to value the stock today, and GAAP is the "widest we have on record," JPMorgan analyst Stephen Tusa tells investors in a research note. The difference is around 50%, higher than ever seen during prior CEO Jeff Immelt's tenure, with "still worst-in-class" consensus free cash flow conversion, Tusa writes in a note titled "Quality vs. Quantity: When Will GEs EPS Recouple and Align with Peers? And Other Notable Items." The analyst keeps an Underweight rating on General Electric with an $11 price target.
05/14/18
05/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with a Buy at Gabelli. 2. Western Digital (WDC) initiated with an Overweight at JPMorgan. 3. GrafTech (EAF) initiated with an Overweight at JPMorgan and an Outperform at RBC Capital. 4. Surface Oncology (SURF) initiated with an Outperform at Evercore ISI and Cowen as well as a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
GABE
05/14/18
INITIATION
GABE
Buy
General Electric initiated with a Buy at Gabelli
Gabelli analyst Justin Bergner initiated coverage on General Electric with a Buy and $22.50 price target. Bergner believes General Electric has the right leadership in place, with high quality assets in Aviation and Healthcare, that provide a margin of safety, and a path to de-leverage which does not require a fire sale of assets.
XOM Exxon Mobil
$82.01

0.23 (0.28%)

04/23/18
RAJA
04/23/18
UPGRADE
RAJA
Market Perform
Exxon Mobil upgraded to Market Perform from Underperform at Raymond James
04/23/18
RAJA
04/23/18
UPGRADE
RAJA
Market Perform
Exxon Mobil upgraded to Market Perform on valuation at Raymond James
As previously reported, Raymond James upgraded Exxon Mobil to Market Perform from Underperform. Analyst Pavel Molchanov said Exxon's dividend yield has widened ot a near-record level of 3.9% and there is a realistic chance the company will reinstate a share buyback in the near future.
04/10/18
BOFA
04/10/18
NO CHANGE
Target $100
BOFA
Buy
Exxon Mobil added to US 1 List at BofA/Merrill
BofA/Merrill analyst Doug Leggate added ExxonMobile to the US 1 List telling investors shares are discounting the lowest long-term oil price in the sector at $48/bbl. Leggate believes Exxon's upstream portfolio leverage is being overlooked following the collapse in oil prices and shares are poised for a recovery following year-to-date lagging performance. Leggate rates Exxon Mobile a Buy with a $100 price target.
04/23/18
04/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Michael Kors (KORS) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the company is in the "middle innings" of a turnaround and is nearing an inflection point. 2. Verizon (VZ) upgraded to Overweight from Equal Weight at Barclays with analyst Amir Rozwadowski saying the company is better positioned than the current valuation implies. 3. Under Armour (UA, UAA) upgraded to Hold from Sell at Deutsche Bank with analyst Paul Trussell saying estimates for the first quarter and fiscal 2018 earnings are attainable, reflecting improved sell-through of new products and a commitment to cost reduction. 4. Hanesbrands (HBI) upgraded to Buy from Hold at Stifel with analyst Jim Duffy noting that the Champion brand is experiencing positive momentum in the lifestyle apparel space while its acquisitions in recent years have diversified the revenue mix and improved the overall portfolio's characteristics. 5. Exxon Mobil (XOM) upgraded to Market Perform from Underperform at Raymond James with analyst Pavel Molchanov saying Exxon's dividend yield has widened at a near-record level of 3.9% and there is a realistic chance the company will reinstate a share buyback in the near future. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WMT Walmart
$86.07

1.56 (1.85%)

05/10/18
LOOP
05/10/18
NO CHANGE
Target $87
LOOP
Hold
Walmart price target lowered to $87 from $92 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Walmart to $87 and kept his Hold rating after the company's $16B investment in Flipkart. The analyst is positive on the deal longer term, given that India's retail market is expected to grow at 9% per year over the next 5 years and in light of the company's minimal store presence in India. In the medium term however, Wolf says the investment will be "meaningfully dilutive" to earnings, weighing on the stock.
05/15/18
SPHN
05/15/18
NO CHANGE
Target $108
SPHN
Overweight
Walmart Q1 expectations achievable, says Stephens
Stephens analyst Ben Bienvenu said he believes that consensus expectations regarding Walmart's Q1 results are achievable, though he noted that e-commerce growth in the quarter may come in below the company's annual guidance for about 40% growth. Still, easier e-commerce comparisons as the year progresses make its annual goals doable and Bienvenu remains confident that Walmart is one of the best positioned retailers he covers, he tells investors. He maintains an Overweight rating and $108 price target on Walmart ahead of the company's earnings report due on Thursday.
05/10/18
MSCO
05/10/18
NO CHANGE
Target $93
MSCO
Equal Weight
Walmart deal for Flipkart more dilutive than anticipated, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that news reports heading up to Walmart's (WMT) deal for a majority stake in Flipkart had predicted a $12B transaction for about 60% of a business generating operating losses in the $1B range. However, the higher than expected magnitude of losses Walmart would absorb in India significantly raises the stakes on the trajectory of its U.S. business and clouds the near-term path, he said. He also questions why the company is investing outside the U.S. market, stating that it could have instead accelerated its third-party marketplace infrastructure, stepped up its partnership with Google Home (GOOG) to better compete with Amazon's (AMZN) Alexa, or intensified domestic investments in price and fulfillment. However, he does add that the deal prevents Amazon, for now, from building an "insurmountable" advantage in the important Indian market. Gutman lowered his price target on Walmart to $93 from $99 after the deal was more dilutive than anticipated and keeps an Equal Weight rating on the shares.
05/16/18
MKMP
05/16/18
NO CHANGE
Target $93
MKMP
Buy
Target to benefit from strong digital sales, says MKM Partners
MKM Partners analyst Patrick McKeever kept his Buy rating and $93 price target on Target Corp (TGT) ahead of its Q1 earnings next week. The analyst says the aggressive Street consensus for earnings is "doable" in spite of the negative impact from cold weather in the East, noting that the quarter will likely see more strong growth in digital sales driven by more "expedient" fulfillment and new orders. McKeever adds that despite the 12% run in the stock price year-to-date, its valuation is still 3.4 points below that of Walmart (WMT) on "overly pessimistic" investor sentiment. The analyst says Target remains his "Top Pick" in the space in 2018.
GM General Motors
$38.03

1.07 (2.90%)

04/24/18
MSCO
04/24/18
NO CHANGE
Target $48
MSCO
Overweight
Morgan Stanley raises value estimate for GM's Cadillac brand to $15B
Morgan Stanley analyst Adam Jonas modeled Cadillac financials out to 2028, assuming a 2017-2028 unit volume CAGR of about 4% for the General Motors brand. He notes this is modestly higher than his previous forecast of closer to 3%, citing expectations for a model strategy closely aligned with transportation-as-a-service trends in China and the U.S., Jonas tells investors. He raised his valuation of Cadillac to $15B from $13B and said he sees scope for new GM management to highlight its "hidden value" through improved financial disclosure and structural changes. Jonas maintains an Overweight rating on GM shares.
05/15/18
PIPR
05/15/18
NO CHANGE
Target $57
PIPR
Overweight
GM valuation does not reflect robo-taxi business, says Piper Jaffray
Piper Jaffray analyst Alexander Potter says General Motors' "budding" robo-taxi business is wrongly being valued at zero. The analyst's city-by-city ride-hailing model indicates a market opportunity that could exceed $1 trillion in the U.S. alone. GM's "valuation does not reflect this opportunity (not by a longshot)," Potter tells investors in a research note. He thinks investors should be buying the stock and upped his price target for the shares to $57 from $52. The analyst's sum-of-the-parts based price target now implies 56% upside to the current share price. He keeps an Overweight rating on GM.
04/09/18
04/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. 2. TD Ameritrade (AMTD) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Carrier saying he views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. 3. Comerica (CMA) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he sees several levers that should drive above average earnings per share growth over the next two years, including margin expansion, potential resumption of loan growth, and above average capital returns. 4. Agilent (A) upgraded to Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools. 5. Discover (DFS) and Ally Financial (ALLY) were upgraded to Equal Weight from Underweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/27/18
SBSH
04/27/18
NO CHANGE
SBSH
Buy
Citi keeps Street-high $70 price target on General Motors
Citi analyst Itay Michaeli raised his estimates for General Motors on the Q1 beat and keeps a Street-high price target on the shares of $70. Further, the analyst continues to have a $134 per share long-term upside potential case. GM delivered a solid Q1 with "various put/takes mostly owing to planned truck downtime ahead of the upcoming product launch," Michaeli tells investors in a post-earnings research note. He notes management reiterated that 2019 should see core earnings improvement.
CLF Cleveland-Cliffs
$8.74

0.165 (1.93%)

05/09/18
05/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) initiated with a Buy at Seaport Global. 2. Amneal Pharmaceuticals (AMRX) initiated with a Buy at Deutsche Bank. 3. Iridium (IRDM) initiated with a Buy at BWS Financial. 4. ServiceMaster (SERV) initiated with a Buy at Buckingham while Rollins (ROL) was initiated with a Neutral at Buckingham. 5. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/18
GSCO
03/20/18
INITIATION
Target $8
GSCO
Neutral
Cleveland-Cliffs initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Matthew Korn started Cleveland-Cliffs with a Neutral rating and $8 price target while rolling out coverage on the Americas Metals & Mining sector with an Attractive view.
04/23/18
CLKS
04/23/18
UPGRADE
CLKS
Buy
Cleveland-Cliffs upgraded to Buy from Neutral at Clarksons Platou
05/09/18
GHSC
05/09/18
INITIATION
Target $10
GHSC
Buy
Cleveland-Cliffs initiated with a Buy at Seaport Global
Seaport Global analyst Mark Levin initiated Cleveland-Cliffs with a Buy and $10 price target citing strong cash flows, long-term contracts, and gradual shift toward serving the US electric arc furnace market through the development of its first hot briquetted iron facility in Ohio.
CL Colgate-Palmolive
$62.09

0.45 (0.73%)

04/20/18
DBAB
04/20/18
NO CHANGE
Target $80
DBAB
Hold
Deutsche Bank downgrades Procter & Gamble, Church & Dwight to Hold
Deutsche Bank analyst Steve Powers downgraded both Procter & Gamble (PG) and Church & Dwight (CHD) to Hold from Buy saying Household & Personal Care is "in a tough spot." The analyst expects incremental pricing pressure to build over the course of 2018 in many categories. Perhaps as a result of tax reform, combined with pre-existing competition, retailers and manufacturers seem willing to reinvest aggressively in order to preserve share, Powers tells investors in a research note. He views this as a "troublesome set-up" for Household & Personal Care names. Along with the two downgrades, the analyst lowered his price targets for Kimberly-Clark (KMB), Edgewell Personal (EPC), Colgate-Palmolive (CL) and Clorox (CLX).
04/30/18
04/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wayfair (W) downgraded to Neutral from Outperform at Wedbush with analyst Seth Basham citing rising CAC and profitability pressures. 2. JetBlue (JBLU) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker saying a lack of pilot progress, a "paucity of international RASM exposure," and the "uphill battle" to rein in non-labor costs represent "burdens" for JetBlue shareholders. 3. Owens Corning (OC) downgraded to Outperform from Top Pick at RBC Capital with analyst Michael Eisen citing the company's first quarter earnings miss. 4. Colgate-Palmolive (CL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Dara Mohsenian saying the company posted weak organic sales in Q1 and pointed out on its associated call that emerging markets are decelerating. 5. Pinnacle Foods (PF) downgraded to Neutral from Buy at Buckingham with analyst Eric Larson citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/30/18
MSCO
04/30/18
DOWNGRADE
Target $69
MSCO
Equal Weight
Colgate-Palmolive downgraded to Equal Weight on EM slowing at Morgan Stanley
As previously reported, Morgan Stanley analyst Dara Mohsenian downgraded Colgate-Palmolive to Equal Weight from Overweight after the company posted weak organic sales in Q1 and pointed out on its associated call that emerging markets are decelerating. Emerging markets, ,as well as a "strategic potential halo," are the key driver of Colgate's premium valuation, Mohsenian tells investors. With Colgate's topline growth outlook compressing closer to peers, the analyst lowered his FY18 and FY19 EPS estimates and cut his price target on the stock to $69 from $80.
04/30/18
MSCO
04/30/18
DOWNGRADE
MSCO
Equal Weight
Colgate-Palmolive downgraded to Equal Weight from Overweight at Morgan Stanley
WB Weibo
$103.85

-0.67 (-0.64%)

04/19/18
DBAB
04/19/18
INITIATION
Target $128
DBAB
Buy
Sina resumed with a Buy from Hold at Deutsche Bank
Deutsche Bank analyst Eileen Deng resumed coverage of Sina (SINA) with a Buy rating and $128 price target. Deutsche Bank, under a different analyst, had a Hold rating on the shares when suspending coverage earlier this year. Deng sees Sina benefiting from growth at subsidiary Weibo (WB).
03/13/18
JEFF
03/13/18
NO CHANGE
Target $160
JEFF
Buy
Weibo price target raised to $160 from $150 at Jefferies
Jefferies analyst Karen Chan raised her price target for Weibo to $160 saying the combination of user growth, time spent, ad pricing improvement and diversifying video ad products gives the company the "right formula in further scaling up monetization efficiency." The analyst believes Weibo's "competitive moat" is underpinned by its young user base, open social media nature and brand ad value. She keeps a Buy rating on the shares.
05/10/18
BNCH
05/10/18
NO CHANGE
Target $159
BNCH
Buy
Sina price target lowered to $159 from $174 at Benchmark
Benchmark analyst Fawne Jiang said that Sina (SINA) reported "solid" Q1 results, which were mainly driven by robust growth at Weibo (WB). She expects Sina to remain a key beneficiary of Weibo's multifaceted growth and believes Sina shares are undervalued, leading her to maintain a Buy rating on the name. However, Jiang lowered her price target on Sina shares to $159 to account for changes in her sum-of-the-parts valuation.
02/14/18
BNCH
02/14/18
NO CHANGE
Target $148
BNCH
Buy
Weibo price target raised to $148 from $110 at Benchmark
Benchmark analyst Fawne Jiang raised her price target on Weibo shares to $148 following the company's "solid" Q4 report and "upbeat" Q1 revenue guidance, stating that she expects healthy user growth, enhanced user engagement, further wallet share gains and improving monetization efficiency ahead. The analyst, who also notes the potential for upside from new business initiatives, keeps a Buy rating on Weibo shares.
NRG NRG Energy
$33.74

-0.01 (-0.03%)

02/23/18
UBSW
02/23/18
INITIATION
Target $21
UBSW
Neutral
Vistra Energy initiated with a Neutral at UBS
UBS analyst Daniel Ford started Vistra Energy (VST) with a Neutral rating and $21 price target. The analyst views the shares as fairly valued without the Dynegy (DYN) deal and prefers shares of NRG Energy (NRG).
02/23/18
UBSW
02/23/18
INITIATION
Target $33
UBSW
Buy
NRG Energy initiated with a Buy at UBS
UBS analyst Daniel Ford started NRG Energy with a Buy rating and $33 price target. The analyst sees the stock moving to his price target as asset sales close and return of capital plans are revealed at the analyst day on March 27.
08/16/17
DBAB
08/16/17
NO CHANGE
Target $38
DBAB
Buy
NRG Energy shares have 50% more upside, says Deutsche Bank
Deutsche Bank analyst Abe Azar raised his price target for NRG Energy shares to $38 from $27 to reflect the company's planned transformation. Even with the rally year-to-date, NRG is still trading at an "unwarranted significant discount to peers," Azar tells investors in a research note titled "Baby, we were born to run." The analyst believes the stock has an additional 50% upside and reiterates a Buy rating on the name. Asset sales throughout the year and an investor day early next year set up a "favorable catalyst calendar and should lead to the stock to re-rate higher," Azar writes.
07/13/17
LEHM
07/13/17
NO CHANGE
Target $27
LEHM
Overweight
NRG Energy price target raised to $27 from $20 at Barclays
Barclays analyst Daniel Ford raised his price target for NRG Energy to $27 saying the company's transformation plan is "significantly accretive." NRG's plan to sell between a 50%-100% stake in NRG Yield and Renewables, plus 6GWs of conventional generation can achieve management's projected $2.0B-$4.5B in cash proceeds and reduction of $8.7B in debt, Ford tells investors in a research note. His upside case has $11 per share of valuation accretion to $38 per share. The analyst reiterates an Overweight rating on the shares.
IMMU Immunomedics
$19.51

0.725 (3.86%)

11/14/17
JEFF
11/14/17
NO CHANGE
Target $16
JEFF
Buy
Jefferies disagrees with yesterday's selloff in Immunomedics
Immunomedics closed down 19% yesterday largely due to interim overall survival data for IMMU-132 and concerns the FDA will require Phase III overall survival data for approval, Jefferies analyst Matthew Andrews tells investors in a research note. The analyst disagrees, and keeps a Buy rating on the shares with a $16 price target. The progression-free survival is the Phase III Special Protocol Assessment's primary endpoint, while the overall survival data may ultimately be confounded by patients' use of other drugs after progression, Andrews tells investors in a research note. Precedent for objective response rate/duration of response exists with FDA breakthrough therapy approvals of 12 solid tumor drugs, some with less robust efficacy than IMMU-132, the analyst adds.
11/14/17
COWN
11/14/17
NO CHANGE
Target $15
COWN
Outperform
Immunomedics drug survival rate disappointing but approval likely, says Cowen
Cowen analyst Phil Nadeau said the overall survival rate for Immunomedics' IMMU-132 showed a decrease, which was disappointing, but the response rate is still well above the current standard of care. As a result, the analyst believes it still appears likely to get accelerated FDA approval. Nadeau reiterated his Outperform rating and $15 price target on Immunomedics shares.
12/06/17
JEFF
12/06/17
NO CHANGE
JEFF
Buy
Immunomedics breast cancer data continue to look 'very solid,' says Jefferies
Jefferies analyst Matthew Andrews says the totality of Immunomedics' Phase II breast cancer data for IMMU-132 "continue to look very solid." Importantly, there was no clinically meaningful decrease in objective response rate per blinded central review, Andrews tells investors in a research note after the company announced updated results. The analyst reiterates a Buy rating and believes the data is sufficient to support FDA accelerated approval.
01/24/18
JEFF
01/24/18
NO CHANGE
Target $22
JEFF
Buy
Immunomedics price target raised to $22 from $16 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Immunomedics to $22 saying his analysis suggests a 98% FDA approval probability of IMMU-132. The shares could be worth $27 on approval, Andrews tells investors in a research note. He keeps a Buy rating on Immunomedics.

TODAY'S FREE FLY STORIES

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LNC

Lincoln National

$68.89

-0.555 (-0.80%)

16:24
05/25/18
05/25
16:24
05/25/18
16:24
Syndicate
Breaking Syndicate news story on Lincoln National »

Lincoln National files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$2.63

0.075 (2.94%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Digital Ally »

Digital Ally files $25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.58

-0.005 (-0.32%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$35.34

0.08 (0.23%)

16:21
05/25/18
05/25
16:21
05/25/18
16:21
Hot Stocks
HFF Inc. announces $640M sale of 5 Bryant Park office tower in Manhattan »

HFF announces the $640M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/25/18
05/25
16:20
05/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for May 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMED

OncoMed

$2.81

0.06 (2.18%)

16:19
05/25/18
05/25
16:19
05/25/18
16:19
Syndicate
Breaking Syndicate news story on OncoMed »

OncoMed files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTEM

Molecular Templates

$7.02

0.34 (5.09%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Syndicate
Breaking Syndicate news story on Molecular Templates »

Molecular Templates files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

, USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.1K…

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

GLD

SPDR Gold Trust

$123.21

-0.4 (-0.32%)

FXE

Euro Currency Trust

$111.98

-0.62 (-0.55%)

FXC

CurrencyShares Canadian Dollar Trust

$76.07

-0.37 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.20

0.1 (0.10%)

16:15
05/25/18
05/25
16:15
05/25/18
16:15
Periodicals
Disney cuts opening weekend sales forecast for 'Solo', Bloomberg says »

Disney cut its domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMSA

Fairmount Santrol

$5.51

-0.26 (-4.51%)

16:11
05/25/18
05/25
16:11
05/25/18
16:11
Hot Stocks
Fairmount Santrol, Unimin receive final merger approval »

Fairmount Santrol and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBL

RumbleON

$4.88

0.16 (3.39%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files $20M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$2.25

0.04 (1.81%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on Ageagle Aerial Systems »

Ageagle Aerial Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$0.82

(0.00%)

16:08
05/25/18
05/25
16:08
05/25/18
16:08
Hot Stocks
Appliance Recycling receives noncompliance notice from NASDAQ »

Appliance Recycling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$51.62

-1.13 (-2.14%)

16:06
05/25/18
05/25
16:06
05/25/18
16:06
Hot Stocks
CIT Group names Marisa Harney chief risk officer »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.81

(0.00%)

16:04
05/25/18
05/25
16:04
05/25/18
16:04
Hot Stocks
Breaking Hot Stocks news story on Trivago »

Par Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.